Clinical Trial Update: Use of Trastuzumab to Induce Increased ER Expression in ER-negative/Low, Her-2/Neu Positive Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study tested whether trastuzumab can increase estrogen receptor expression in ER-negative/low, HER2-positive breast cancer; the trial was terminated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Trastuzumab (trastuzumab)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2013-10-15